Amarin Corp Plcuk (AMRN) Short-term Investments (2020 - 2026)
Amarin Corp Plc\Uk (AMRN) posted quarterly Short-term Investments of $171.1 million for Q2 2026, up 13.44% year-over-year from $150.8 million in Q2 2025, and down 3.22% quarter-over-quarter from $176.8 million in Q1 2026.
Amarin Corp Plcuk (AMRN) Short-term Investments (2020 - 2026) Analysis & Trends
Amarin Corp Plc\Uk (AMRN) has reported Short-term Investments for 7 consecutive years, with $171.1 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Short-term Investments rose 13.44% year-over-year to $171.1 million; the TTM figure through Jun 2026 stood at $171.1 million (up 13.44% YoY), while the FY2025 annual figure was $167.9 million, down 3.03% from the prior year.
- Short-term Investments retreated to $171.1 million in Q2 2026 per AMRN's latest filing, from $176.8 million in the prior quarter.
- Across five years, Short-term Investments topped out at $176.8 million in Q1 2026 and bottomed at $49.8 million in Q3 2023.
- Historically, Short-term Investments has averaged $124.9 million across 5 years, with a median of $132.4 million in 2022.
- Annual changes were most pronounced in 2022 — Short-term Investments tumbled 75.34% — and 2024, when it soared 198.51%.
- Amarin Corp Plc\Uk's Short-term Investments stood at $91.7 million in 2022, then soared by 32.4% to $121.4 million in 2023, then soared by 42.65% to $173.2 million in 2024, then slipped by 3.03% to $167.9 million in 2025, then increased by 1.89% to $171.1 million in 2026.
- Business Quant data shows AMRN's Short-term Investments at $171.1 million in Q2 2026, $176.8 million in Q1 2026, and $167.9 million in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Amarin Corp Plcuk | 5.86 Bn | 5.54 Bn | 14.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 171.10 Mn |
| Mar 31, 2026 | 176.80 Mn |
| Dec 31, 2025 | 167.93 Mn |
| Sep 30, 2025 | 163.80 Mn |
| Jun 30, 2025 | 150.83 Mn |
| Mar 31, 2025 | 162.30 Mn |
| Dec 31, 2024 | 173.18 Mn |
| Sep 30, 2024 | 148.80 Mn |
| Jun 30, 2024 | 90.74 Mn |
| Mar 31, 2024 | 94.24 Mn |
| Dec 31, 2023 | 121.41 Mn |
| Sep 30, 2023 | 49.85 Mn |
| Jun 30, 2023 | 79.92 Mn |
| Mar 31, 2023 | 113.00 Mn |
| Dec 31, 2022 | 91.70 Mn |
| Sep 30, 2022 | 63.20 Mn |
| Jun 30, 2022 | 85.23 Mn |
| Mar 31, 2022 | 143.41 Mn |
| Dec 31, 2021 | 234.67 Mn |
| Sep 30, 2021 | 256.30 Mn |